Thyroid carcinomas comprise distinct pathologic subtypes. However, advancements in
characterizing the molecular tumorigenesis of thyroid cancers have changed the treatment …

Thyroid cancer is the most common endocrine malignancy with almost one million people
living with thyroid cancer in the United States. Although early-stage well-differentiated …

Thyroid cancer can be largely classified as well-differentiated, poorly differentiated,
medullary and anaplastic. Differentiated thyroid cancer (DTC) includes follicular and …

The treatment of advanced thyroid cancer has undergone rapid evolution in the last decade,
with multiple kinase inhibitor drug approvals for each subtype of thyroid cancer and a …

Objective The treatment landscape for thyroid cancers has changed rapidly with the
availability of kinase inhibitors against VEGFR, BRAF, MEK, NTRK, and RET. We provide an …

Until recently, patients with advanced thyroid cancers had limited options for systemic
treatment. With the introduction of tyrosine kinase inhibitors (TKIs) as a promising new class …

Thyroid cancer, with the exception of anaplastic thyroid cancer, typically has very favorable
outcomes with the standard therapy. However, those that persist, recur, or metastasize are …

Advanced thyroid cancer is not amenable to therapy with conventional cytotoxic
chemotherapy. However, newer advances in the understanding of the molecular …

Clinical Efficacy of Targeted Biologic Agents as Second‐Line Therapy of Advanced Thyroid
Cancer | The Oncologist | Oxford Academic Skip to Main Content Advertisement Oxford Academic …

Thyroid cancer typically has a good outcome following standard treatments, which include
surgery, radioactive iodine ablation for differentiated tumours and treatment with thyrotropine …